Dole just issued a recall for its fresh blueberries after it was found that it could be potentially contaminated with cyclospora, a parasite that, when consumed by people through food or drink, can cause an intestinal illness called cyclosporiasis.
The affected batches of Dole blueberries
According to USA Today, Dole recalls not all the batches of its fresh blueberries but just a limited number of cases for fear of cyclospora contamination. Based on the note from the U.S. Food and Drug Administration, the American agricultural multinational corporation headquartered in Westlake Village, California, has voluntarily recalled some blueberries in different packaging sizes that were packed between the dates from May 28 and June 9.
In the recall sheet, the Dole blueberries affected are in packages of 6, 18, and 24 ounces. Pint sizes are also included in the recall. The consumers who purchased the Dole Fresh Blueberries that were packed on the given dates are asked to discard them immediately.
Fortunately, the FDA stated that so far, they have not received any complaints of illnesses yet that are linked to the affected Dole blueberries. The people are also warned to watch out for signs of cyclospora infection.
If eaten, the person could experience severe abdominal pain, nausea, body aches, diarrhea, and fatigue. Infected individuals must seek medical help, and usually, the doctor will prescribe antibiotics to kill and flush out the parasite.
The affected Dole Blueberries
As mentioned on the official recall posted on the FDA website, the affected Dole Blueberries were sold and distributed in New York, Wisconsin, Maine, and Illinois. The product was also sent to at least two provinces in Canada, including British Columbia and Alberta.
“No other Dole products are included in the recall,” the FDA wrote in the notice. “Only Dole Fresh Blueberries with the exact UPC and lot code combinations identified above are included in the recall. Consumers who have any of the recalled products should not consume it, but rather discard it immediately.”


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Oil Prices Ease in Asia as Geopolitical Risks Clash With Weak Demand Outlook
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Gold Price Breaks $4,500 as Safe-Haven Demand and Rate Cut Bets Fuel Rally
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
BOJ Governor Signals Gradual Rate Hikes as Japan’s Inflation Nears 2% Target
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Italy Fines Apple €98.6 Million Over App Store Dominance
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
U.S. Stock Index Futures Steady After S&P 500 Hits Record on Strong Economic Data
Russian Stocks End Lower as Energy and Mining Shares Weigh on MOEX Index
Gold Prices Surge to Record Highs as Geopolitical Tensions Fuel Safe-Haven Demand
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Tokyo Core Inflation Stays Above BOJ Target, Strengthening Case for Further Rate Hikes
IMF Reaches Staff-Level Agreement With Egypt, Opening Path to $3.8 Billion in Funding
Asian Stock Markets Trade Flat as Holiday Liquidity Thins and BOJ Minutes Watched
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 



